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The proinsulin C-peptide has molecular, cellular and organismal activities but lacks disease-
associated mutations or short-term loss-of-function effects. This dilemma between activity and
function may be explained from its evolutionary setting with insulin as an ancestral partner. The
charge, approximate length and ﬂexibility of C-peptide are all that is required for the insulin inter-
actions, while remaining aspects are free to evolve, where new bioactivities can emerge. They can
initially be transient, weak, and non-functional, but may gradually be consolidated. In this
manner, C-peptide may have acquired multiple bioactivities, explaining why some yet have limited
functions but could represent early-stage hormonal-like activities.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
C-peptide, constituting most of the connecting part between the
insulin A- and B-chains, is found in all known proinsulins. It is
excised during insulin maturation and secreted into the blood
stream at a 1:1 M ratio with insulin [1]. It exhibits a much higher
sequence variation than the neighboring insulin chains (Fig. 1)
and was initially regarded as a by-product of insulin synthesis or
as a part promoting insulin folding and secretion. The latter view
is still valid, but has lately been extended by many reports on an
overwhelming range of further bioactivities. When C-peptide is
viewed in relation to its insulin neighbor that has a highly con-
served sequence and a well-deﬁned structure, it is not apparent
how it could exert hormone-like actions. However, the large
degree of freedom afforded by the evolutionary setting of
C-peptide as a linking segment with little sequence requirements
make it an ideal site for the generation of new biological activities.
The concept of C-peptide as an evolutionary ‘‘playground’’ can pro-
vide an explanation for the wide range of its biological activities
and their yet variable importance for physiological functions.2. Dilemma between activity and function
Let us ﬁrst consider the bioactivities. The fact that C-peptide is
bioactive is supported by strong evidence reaching from the
molecular to the cellular and organismal levels (Table 1). For exam-
ple, C-peptide has been shown to bind to cellular membranes [2],
to elicit a number of signaling events [3–7], to be displaced by ana-
logs [2] and to have activities interfered with by pertussis toxin [3],
all suggesting analogies with hormonal ligands binding to their
receptors. In fact, a G-protein coupled receptor (GPCR) has been
suggested but not established to be activated by C-peptide [8],
and such a mechanism has been inferred to be limited to single res-
idues like in neurotensin and glucagon interactions with their
receptors [9]. Similarly, C-peptide can enter cells and nucleoli, bind
to histones and stimulate rRNA synthesis [10]. In addition, C-pep-
tide interacts with insulin as part of the secretory system that co-
secretes these two peptides, IAPP and further components from
pancreatic b-cells [11,12]. Some C-peptide effects extend to the
organismal level, with C-peptide measurably affecting glomerular
ﬁltration rates, circulation and nerve conductivity [13–15].
C-peptide has also been suggested to prevent late complications
such as diabetic neuropathy [16], perhaps by chaperoning effects
on insulin [17,18], and diabetes mellitus to be a double-deﬁciency
disease [19].
Despite the evidence of C-peptide activities, the physiological
signiﬁcance of the peptide remains debated, unproven or even dis-
proved. For example, there is no evidence for a short-term fall-out
Fig. 1. Sequence conservation and structural features of C-peptide and insulin. (A) Alignments of the proinsulin sequences formmammals, amphibians, reptiles, birds and ﬁsh
show a consistent pattern of high conservation (dark blue positions) of the insulin A- and B-chains, while C-peptide exhibits considerably lower conservation. (B) The NMR
structure of proinsulin [30] exhibits considerable ﬂexibility in the C-peptide part (green), which includes only a short helical segment, while the insulin moiety (gray) is
tightly folded. The locations of the dibasic cleavage sites at which C-peptide is excised are indicated in red.
Table 1
Reported molecular, cellular, and organismal effects of C-peptide.
Molecular interactions
Insulin desaggregation and chaperoning [17,18,26]
IAPP binding [11,12]
Membrane interactions [2,34]
Histone binding [10]
Cellular actions
Cellular internalization [38]
Activation of RNA transcription [10]
Increased Ca2+ uptake [5]
Activation of GPCR/MAPK signaling [2,6,7]
Altered protein expression [3,4,39]
Effects in diabetic patients
Reduced glomerular hyperﬁltration [15]
Increased nerve conductivity [13,14,16,33]
Improved circulation [4,39]
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fall-out effects from lack of several conventional hormonal ligands.
Similarly, there is a lack of C-peptide disease-associated mutations,a lack of clearly enriched targets in the rRNA synthesis induced by
C-peptide [10], although many transcriptional events are observed,
and a lack of insulin secretion blockage by C-peptide failure
[20,21]. Hence, there is a fundamental dilemma with C-peptide:
despite its bioactivity, it is not known to have a functional impor-
tance typically associated with bioactive peptides [22].
This dilemma has created questions on the interpretation of
C-peptide roles:
⁄ Which of the bioactivities represent physiological function(s) of
C-peptide?
⁄ How important is each function?
⁄ How can a peptide mechanism have speciﬁc functions in spite of
much structural variability?
These questions may not be as complicated as they may ﬁrst
seem. They likely illustrate general rules of molecular evolution.
Interpretation of these rules may cast new views on the functions
of C-peptide, and also on the spread of peptide evolution: some
peptides (or proteins) have strictly deﬁned structures and
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are quite variable and evolving (like C-peptide), and some
extremes may even be independent of evolutionary restrictions,
like recently discussed for amyloidogenic peptides [23].
3. Conserved features linked to insulin interactions
In evolution, structural conservation of any part, once locked
into a functional mechanism, means restrictions on random vari-
ability. Which then are the structural conservations in C-peptide?
Three conservations have been observed [24] and still remain in
recent interpretations [9]: (1) its location in between the insulin
parts, (2) its negative charge from largely conserved glutamic acid
residues, and (3) its irregular center part, with adjacent glycine and
proline residues interrupted by gaps in the alignments [24]. In
addition, single other residues may also be conserved in mammals.
The Glu residues of the two C-peptide ends and the variable center
give the whole C-peptide a tripartite pattern [9].
Experimental evidence shows that these conserved features can
be linked directly to requirements on C-peptide posed by its insu-
lin partner. These requirements are largely biophysical, such as
size and charge, rather than biochemical, such as exact ﬁts or
side-chain geometries. For example, shortening of the link between
the proinsulin A- and B-chains promotes disulﬁde mismatches in
the insulin moiety [25]. Similarly, removal of the acidic residues
in C-peptide impairs proinsulin folding, promotes aggregation
[26], and prevents proteolytic processing [27]. The importance of
the C-peptide negative charge is supported by reports that the
position of Glu-3 has co-evolved with hydrophobic and acidic res-
idues in the insulin A- and B-chains [28]. Similarly, all the four
most conserved Glu residues seem to correlate with insulin charge
interactions and with a 2:1 optimal stoichiometry in insulin/C-
peptide complexes [29]. Further, once the insulin moiety is folded,
the C-peptide segment has to adopt a protruding, loop-like struc-
ture [30]. This explains the observation that removal of the ﬂexible
glycine- and proline-rich middle segment impairs insulin folding
[26].
4. Remaining features linked to C-peptide as an evolutionary
cradle
To fulﬁll its co-evolutionary role with insulin, C-peptide, as
experimentally shown above, is required to retain apparently only
its approximate length, negative charges, and central ﬂexibility.
Hence, much of its structure is not subject to further restrictions
on speciﬁc residues or interactive geometries for fulﬁlling its
insulin interactions, which constitutes its original function as
concluded from the co-synthesis with insulin. The framework of
C-peptide could then be considered as an evolutionary
‘‘playground’’: a sequence that cannot be eliminated and is con-
stantly expressed, but may be altered as long as a few biophysical
requirements are met. Indeed, C-peptide does accept mutations at
a 12–15 times faster rate than its insulin neighbor [24], which indi-
cates less evolutionary constraints on C-peptide.
This unique situation provides a solution to the dilemma that
C-peptide is biologically active but does not appear to be indis-
pensable: when the C-peptide basic structure can be evolutionarily
altered, it can by chance acquire motifs with novel biological activ-
ity, for example new protein interaction sites, resembling
hormonal activities. Once formed, two characteristics of such sites
can be expected: (1) the motif should be relatively short, since
complex motifs are less likely to emerge in the absence of
co-evolution with a target, and (2) the activity should be
non-essential until sufﬁcient time has passed to gradually consol-
idate its physiological importance, which in turn occurs throughco-evolution with other components. The acquired functions could
then be transient features or persist and evolve into physiological
functions depending on a variety of factors such as beneﬁcial
effects and the availability of complementary components. Thus,
natural variation and stepwise emergence of novel activities,
because of the few restrictions in the basic function, could well
lead to the multiplicity but limited physiological function of the
newly added hormonal activities.
5. Segmented bioactivities
Fragment studies have indeed shown that the different biolog-
ical activities of C-peptide are exerted by segments whose patterns
reveal a stepwise emergence [31]. The N-terminal segment (resi-
dues 1–11) contains most of the negative charges important for
proinsulin folding and conserved in co-evolution with insulin
[26,28]. The same segment mediates the desaggregating effect of
C-peptide on insulin molecules [32], which is likely an extension
of its intramolecular chaperone role. The middle segment (residues
12–16), rich in prolines, glycines and gaps confers ﬂexibility. The
distribution of these residues extends from a scattered pattern in
ﬁsh, birds, reptiles and amphibians toward a poly-glycine stretch
with a central proline in mammals [31]. The turn-like motif that
results from this re-arrangement has been reported to partially
mediate vascular and neural functions of C-peptide in rats [33].
The same region was also suggested to mediate C-peptide mem-
brane interactions at low pH [34]. Lastly, the C-terminal pentapep-
tide (residues 27–31) with a glutamine and glutamic acid has been
found to activate GPCR signaling [35]. This segment is apparently
late in origin and only present in mammals with no corresponding
parts in other phyla [31].6. Hormonogenesis
The view of C-peptide as an evolutionary cradle is in good agree-
ment with the step-wise emergence of its multiple activities, i.e.
hormonogenesis. Similar geneses of new functions occur in pro-
teins, which may form novel enzymes in enzymogenesis [36], as
observed in for example dehydrogenases, in which evolutionary
spreads also vary and even non-expressed, silent forms occur
[37]. As outlined above, the only completely conserved features of
C-peptide have co-evolved with its only established function on
insulin. Its additional activities have apparently arisen from addi-
tions in the already existing proinsulin architecture. As such, they
might represent predecessors to or even emergence of early stages
of hormone-like actions, but still lack the strong physiological
importance normally associated with mature peptide hormones.
It is important to note that essential physiological processes are
often protected by compensatory mechanisms that counteract the
most severe effects of acute loss of function. It may therefore be
possible that the variability of C-peptide is protected by compensa-
tory mechanisms elsewhere, or that C-peptide itself participates in
a compensatory mechanism. In any case, such compensatory rela-
tionships could also be generated by the evolutionary process now
outlined. In short, the basic function of C-peptide with insulin can
explain its multiple bioactivities and lack of correspondingly
strong functional correlations.
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